


CONFIDENTIAL

For HPFB [REDACTED] TGA [REDACTED] use – Obtained in Confidence

PHARMACOVIGILANCE CONFERENCE BETWEEN REPRESENTATIVES OF:

Australia: Commonwealth Department of Health, Therapeutic Goods Administration, Office of Product Review

Canada: Health Canada, Health Products and Food Branch



CONFIDENTIAL

For HPFB/FDA/TGA/Medsafe/HSA use – Obtained in Confidence

10	Restriction of indication for risperidone in dementia to the Alzheimer's type. (HSA) Rationale: In February 2015, Health Canada published a Dear Healthcare Professional Letter regarding the restriction of indication for risperidone in dementia to patients with severe dementia of the Alzheimer type. ¹ Other types of dementia such as vascular and mixed types of dementia are no longer indicated. The Canadian product monograph for Risperdal® has been updated to include the new information. This decision was made after a review of information concerning the risks of cerebrovascular adverse events (CVAEs) among patients with dementia treated with anti-psychotics. The risks of such events were found to be higher in among patients with mixed and vascular types dementia compared to those with Alzheimer type dementia.	Written response	
	References 1. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43797a-eng.php		

